SRSF1 and cancer: Crucially, stable knockdown of SRSF1 increased the accumulation of LC3-II in Gefitinib-resistant cells (Fig. 7c), sensitized the resistant cancer cells to Gefitinib as compared to control (Supplementary Fig. 7a), and inhibited the growth of these Gefitinib-resistant cancer cells as judged by colony formation and growth curve assays (Fig. 7d, e), suggesting depletion of SRSF1 could suppress Gefitinib-resistant cancer cell proliferation at least partially through activating autophagy.